Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Breast Neoplasms 41Carcinoma, Renal Cell 31Neoplasms 18Kidney Neoplasms 17Neuroendocrine Tumors 16Neoplasm Metastasis 13Tuberous Sclerosis 10Prostatic Neoplasms 8Carcinoma 8Lymphoma, Mantle-Cell 7Lymphoma, Large B-Cell, Diffuse 7Hodgkin Disease 7Glioma 7Glioblastoma 7Astrocytoma 7Waldenstrom Macroglobulinemia 6Triple Negative Breast Neoplasms 6Recurrence 6Lymphoma 6Head and Neck Neoplasms 6Stomach Neoplasms 5Ovarian Neoplasms 5Colorectal Neoplasms 5Carcinoma, Neuroendocrine 5Brain Neoplasms 5Sezary Syndrome 4Sarcoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Pancreatic Neoplasms 4Mycosis Fungoides 4

Interventions

Sunitinib 3Everolimus 3cabozantinib 2Temozolomide 2sapanisertib 1motesanib diphosphate 1ibrutinib 1ganitumab 1batifiban 1aflibercept 1X-Rays 1Specimen Handling 1Phantoms, Imaging 1Oxaliplatin 1Octreotide 1Magnetic Resonance Spectroscopy 1Leucovorin 1Fluorouracil 1Doxorubicin 1Cryotherapy 1Capecitabine 1Bevacizumab 1Acupuncture Therapy 1Acupressure 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Adenoma, Islet Cell × Everolimus × Clear all
NCT02264665 2023-11-13

OPALINE

Pfizer

Completed
144 enrolled 26 charts

Adenoma, Islet Cell

NCT00576680 2020-07-09

RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors

Dana-Farber Cancer Institute

Phase 1/2 Completed
43 enrolled 8 charts

Adenoma, Islet Cell

NCT01374451 2016-12-20

COOPERATE-2

Novartis

Phase 2 Terminated
160 enrolled 17 charts
EndocrineNET

Adenoma, Islet Cell, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡